Table 1.
Characteristics of the studies included in the systematic review.
| Author, year | Country | Income classification (WB) | Study Type | Model | Perspective | Time horizon | Discount Rate | Population Age (years) | Index Test | Reference Test |
|---|---|---|---|---|---|---|---|---|---|---|
| Andrés-Gamboa (2008) | Colombia | Upper-middle | CEA | Markov decision model | Payer | Throughout life | 3% | 21‒69 (cytology) | HPV DNA | Cervical smear |
| 30‒69 (HPV DNA) | Pap smear | |||||||||
| Beal (2014) | Mexico | Upper-middle | CEA, CA | Decision Tree Model | Healthcare system | 3 to 5 years | 5% | 35‒64 | HPV DNA | Cervical smear |
| Pap smear | ||||||||||
| Caetano (2006) | Brazil | Upper-middle | CEA | Decision Tree Model | Healthcare system | 1 year | Without Information | 25‒59 | HPV DNA | Cervical smear |
| Pap smear | ||||||||||
| Campos (2015) | India, Nicaragua and Uganda | Lower-middle India and Nicaragua | ACE, BIA | Microsimulation model | Health system and patient | Throughout life | 3% | 25‒50 | HPV DNA | Cervical smear |
| Low: Uganda | Pap smear | |||||||||
| Campos (2017) | Nicaragua | Medium-Low | CEA | Microsimulation model | Health system and patient | Throughout life | 3% | 30‒59 | HPV DNA | Cervical smear |
| Pap smear | ||||||||||
| Flores (2011) | Mexico | Upper-middle | CEA | Decision Tree Model | Healthcare system | 1 year | 3% | 20‒80 | HPV DNA | Cervical smear |
| Pap smear | ||||||||||
| Goldie (2005) | South Africa, India, Peru, Kenya and Thailand | Upper-middle: South Africa, Peru and Thail and Lower-middle: India and Kenya | CEA | Markov decision model | Health system and patient | Throughout life | 3% | 1 × in life: 35 | Hybrid Capture II HPV test | Cervical smear |
| 2 × in life: 35 and 40 | Pap smear | |||||||||
| 3 × in life: 35, 40 and 45 | ||||||||||
| Gutierrez-Delgado (2008) | Mexico | Upper-middle | CEA | Markov decision model | Payer | 20 years/intervention funding | 3% | 25‒64 (cytology) | Hybrid Capture II HPV test | Cervical smear |
| 100 years/health benefits | 30‒69 (HPV DNA) | Pap smear | ||||||||
| Levin (2010) | China | Upper-middle | CEA | Markov decision model | Health system and patient | Throughout life | 3% | 1 × in life: 35 | Hybrid Capture II HPV test and HPV DNA | Cervical smear |
| 2 × in life: 35 and 40 | Pap smear | |||||||||
| 3 × in life: 35, 40 and 45 | ||||||||||
| Mandelblatt (2000). | Thailand | Upper-middle | CBA | Simulation model (Semi-Markov) | Health system and patient | Throughout life | 3% | 35‒55 | Hybrid Capture II HPV test | Cervical smear |
| Pap smear | ||||||||||
| Nahvijou (2014) | Iran | Upper-middle | CMA | Decision Tree Model | Healthcare system | Without Information | Without Information | 35 years | HPV DNA | Cervical smear |
| Pap smear | ||||||||||
| Nahvijou (2016) | Iran | Upper-middle | CEA | Markov decision model | Healthcare system | Throughout life | 3% | 21‒65 | HPV DNA | Cervical smear |
| Pap smear | ||||||||||
| Tantitamit (2015) | Thailand | Upper-middle | CEA | Decision Tree Model | Health system and patient | Without Information | Without Information | Without Information | Hybrid Capture II HPV test | Cervical smear |
| Pap smear | ||||||||||
| Termrungruanglert (2017) | Thailand | Upper-middle | CEA | Markov decision model | Healthcare system | 35 years | 3% | 35‒65 | HPV DNA with 16/18 genotyping | Cervical smear |
| Pap smear | ||||||||||
| Termrungruanglert (2019) | Thailand | Upper-middle | ACE, BIA | Markov decision model | Healthcare system | 10 years | 3.5% | 35‒65 | HPV DNA with 16/18 genotyping | Cervical smear |
| Pap smear |
CEA, Cost-Effectiveness Analysis; CA, Cost Analysis; CBA, Cost-Benefit Analysis; CMA, Cost-Minimization Analysis; BIA, Budget Impact Analysis; WB, World Bank.